Glenmark Pharma gets final USFDA nod for migraine drug

Posted on:16 Mar 2016 15:07:18
Glenmark Pharma gets final USFDA nod for migraine drug
16 March 2016 Current Affairs: GlenmarkBSE 1.46 % Pharma has received final nod from the USFDA to manufacture and market therapeutical equivalent of Endo Pharmaceutical's Frova tablets, used to treat migraine headaches, in the US market. Glenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (USFDA) for Frovatriptan Succinate Tablets, 2.5 mg.the drug is "therapeutical equivalent of Endo Pharmaceutical's Frova tablets 2.5 mg." Quoting IMS data, Glenmark said the approved product has an estimated market size of $87.8 million for the 12 months ended January 2016. The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US. Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India.It manufactures and markets generic formulation products and active pharmaceutical ingredients, both in the domestic and international markets.The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US.
GlenmarkBSE 1.46 % Pharma has received final nod from the USFDA to manufacture and market therapeutical equivalent of Endo Pharmaceutical's Frova tablets, used to treat migraine headaches, in the US market. Glenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (USFDA) for Frovatriptan Succinate Tablets, 2.5 mg.the drug is "therapeutical equivalent of Endo Pharmaceutical's Frova tablets 2.5 mg." Quoting IMS data, Glenmark said the approved product has an estimated market size of $87.8 million for the 12 months ended January 2016. The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US. Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India.It manufactures and markets generic formulation products and active pharmaceutical ingredients, both in the domestic and international markets.The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US.

Daily Current Affairs Videos Video Link
25th March 2019 Current Affairs Video
23rd March 2019 Current Affairs Video
22nd March 2019 Current Affairs Video
21st March 2019 Current Affairs Video
20th March 2019 Current Affairs Video
Watch more Current Affairs Videos

Monthly Current Affairs

Fresherslive telegram Group

Current Affairs Section

Daily Current Affairs Quiz


Subscribe to Current Affairs

Enter your email to get daily current affairs

Current Affairs Weekly PDF

Current Affairs Monthly PDF

Current Affairs Quiz

Current Affairs Monthly PDF Hindi

Currentt Affairs 2019 March

25 MARCH
NEWS
24 MARCH
NEWS
23 MARCH
NEWS
22 MARCH
NEWS

Currentt Affairs 2019 February

28 FEBRUARY
NEWS
27 FEBRUARY
NEWS
26 FEBRUARY
NEWS
25 FEBRUARY
NEWS

Currentt Affairs 2019 January

31 JANUARY
NEWS
30 JANUARY
NEWS
29 JANUARY
NEWS
28 JANUARY
NEWS